Effect on FAAH gene expression in Sabra mouse hypothalamus assessed as change in mRNA level at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 by RT-PCR analysis relative to GAPDH
Effect on CAMKK2 gene expression in Sabra mouse hypothalamus assessed as change in mRNA level at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 by RT-PCR analysis relative to GAPDH
Effect on 5HT1A gene expression in Sabra mouse hypothalamus assessed as change in mRNA level at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 by RT-PCR analysis relative to GAPDH
Effect on CART gene expression in Sabra mouse hypothalamus assessed as change in mRNA level at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 by RT-PCR analysis relative to GAPDH
Effect on NPY gene expression in Sabra mouse hypothalamus assessed as change in mRNA level at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 by RT-PCR analysis relative to GAPDH
Effect on POMC gene expression in Sabra mouse hypothalamus assessed as change in mRNA level at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 by RT-PCR analysis relative to GAPDH
Antiobesity activity in Sabra mouse assessed as change in food consumption at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured after 6 weeks relative to control
Antiobesity activity in Sabra mouse assessed as change in food consumption at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured after 5 weeks relative to control
Antiobesity activity in Sabra mouse assessed as change in food consumption at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured after 3 weeks relative to control
Antiobesity activity in Sabra mouse assessed as change in food consumption at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured after 4 weeks relative to control
Antiobesity activity in Sabra mouse assessed as change in body weight at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured on day 35 relative to control
Antiobesity activity in Sabra mouse assessed as change in body weight at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured on day 39 relative to control
Antiobesity activity in Sabra mouse assessed as change in body weight at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured on day 30 relative to control
Antiobesity activity in Sabra mouse assessed as change in body weight at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured on day 25 relative to control
Antiobesity activity in Sabra mouse assessed as change in body weight at 1 mg/kg, ip administered on day 8, 9, 10, 11, 14, 18, 24 and 32 measured on day 14 relative to control